Black Rock Inc. Exagen Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Exagen Inc. stock. As of the latest transaction made, Black Rock Inc. holds 55,505 shares of XGN stock, worth $104,904. This represents 0.0% of its overall portfolio holdings.

Number of Shares

55,505

Previous 57,835 4.03%

Holding current value

$104,904

Previous $115,000 23.48%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.42 - $2.3 $3,308 - $5,359	-2,330 Reduced 4.03%	55,505 $88,000
Q4 2023 Feb 13, 2024	SELL	$1.45 - $2.39 $13,390 - $22,071	-9,235 Reduced 13.77%	57,835 $115,000
Q3 2023 Nov 13, 2023	SELL	$2.24 - $2.93 $15,599 - $20,404	-6,964 Reduced 9.41%	67,070 $162,000
Q2 2023 Aug 11, 2023	BUY	$2.36 - $3.48 $4,273 - $6,302	1,811 Added 2.51%	74,034 $214,000
Q1 2023 May 12, 2023	BUY	$2.23 - $2.9 $1,282 - $1,667	575 Added 0.8%	72,223 $175,000

Q4 2022 Feb 13, 2023	SELL	$2.1 - $3.4 $4,605 - $7,456	-2,193 Reduced 2.97%	71,648 $171,000
Q3 2022 Nov 14, 2022	SELL	$3.43 - $8.68 $514 - $1,302	-150 Reduced 0.2%	73,841 $200,000
Q2 2022 Aug 12, 2022	SELL	$4.18 - $7.74 $2.08 Million - $3.85 Million	-497,322 Reduced 87.05%	73,991 $425,000
Q1 2022 May 12, 2022	SELL	$7.12 - $11.06 $91,335 - $141,877	-12,828 Reduced 2.2%	571,313 $4.59 Million
Q4 2021 Feb 10, 2022	BUY	$8.97 - $14.08 $2,269 - $3,562	253 Added 0.04%	584,141 $6.79 Million
Q3 2021 Nov 09, 2021	SELL	$10.25 - $15.21 $18,265 - $27,104	-1,782 Reduced 0.3%	583,888 $7.94 Million
Q2 2021 Aug 11, 2021	BUY	$12.4 - $17.92 $7.26 Million - $10.5 Million	585,670 New	585,670 $8.78 Million

Others Institutions Holding XGN

# of Institutions

Shares Held

6.21M

Call Options Held

1.6K

Put Options Held

4.1K

View Full List

About EXAGEN INC.

Ticker XGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 16,260,400
Market Cap $30.7M
Description
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...

More about XGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account